Lipella Pharma Q1 net loss $1.1M; cash $4.0M; Phase 2a LP-10 positive

LIPELLA PHARMACEUTICALS INC.

2023-Q1 EPS reported -$0.19 revenue$118,048

Net loss of ~$1.1M for Q1 2023; cash, equivalents, and marketable securities ~$4.0M as of March 31, 2023.
Phase 2a trial for LP-10 (hemorrhagic cystitis) showed positive safety and efficacy top line results; Type B FDA meeting planned in coming months.
Established Scientific Advisory Board for LP-310 (oral lichen planus) with five experts in oral medicine.
Entered manufacturing collaboration with Cook MyoSite to support LP-10 IND application.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LIPELLA PHARMACEUTICALS INC. reported quarter ended March 31, 2023 results: net income approximately $1.1 million.

Period: quarter ended March 31, 2023
Net income: approximately $1.1 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2023 was approximately $1.1 million.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

LIPELLA PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001753926-23-000678

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.